CD 147 and HPV 16 oncoprotein expression in cervical squamous cell carcinoma and the clinical implications

Yu Zhao,Jing Luan,Fei Feng,Zhi-Nan Chen
2017-01-01
Abstract:CD147 participates in tumour invasion and metastasis in various human malignancies. Human papillomavirus 16 (HPV16) oncoproteins HPV16E6 and HPV16E7 are frequently observed in cervical squamous cell carcinoma (CSCC). HPV16E6 and HPV16E7 induce carcinogenesis by degrading tumour suppressor proteins p53 and pRB, respectively. In this study, we investigated the expression levels of CD147, HPV16E6, HPV16E7, p53 and pRB by immunohistochemical analysis of CSCC tissues from 57 first-visit patients. The positive rates of CD147, HPV16E6, HPV16E7 and p53 expression were significantly higher in the cancer tissues than in the para-cancer tissues (P<0.001, P=0.021, P<0.001, P<0.001, respectively). In particular, CD147 was expressed in 84.2% of cancer tissues and 5.3% of para-cancer tissues. CD147 expression and its co-expression with HPV16E6 (CD147-HPV16E6 co-expression) both correlated with regional lymph node metastasis (N stage, P=0.013, P=0.014), FIGO stage (P=0.001, P=0.001), and tumour size (P=0.006, P=0.049). Furthermore, CD147 expression was positively associated with HPV16E6 (P=0.047), p53 (P=0.028) and pRB (P=0.022) expression. CD147-HPV16E6 co-expression was also associated with p53 expression (P=0.022). In conclusion, CD147 was specifically expressed in CSCC tissues and could be a promising CSCC oncotarget. Both CD147 expression and CD147-HPV16E6 co-expression correlated with tumour malignancy and poor prognosis, making them both potential cancer-related biomarkers in CSCC therapy. In addition, the interaction among CD147, HPV16E6 and p53 might be involved in CSCC progression.
What problem does this paper attempt to address?